ArticleJACC. Case reports2026
Orthotopic Transcatheter Tricuspid Valve Replacement After Heterotopic Caval Valve Failure.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeterotopic caval valve implantation has emerged as a compassionate transcatheter option for patients with severe tricuspid regurgitation (TR) deemed unsuitable for edge-to-edge repair. However, long-term durability and management of device failure remain poorly defined. CASE SUMMARY: We report the case of a 70-year-old woman with prior heterotopic TricValve implantation because of massive TR, who presented with recurrent right-sided heart failure secondary to inferior vena cava prosthetic dysfunction. Multimodality imaging revealed the known significant TR and severe degeneration of the heterotopic valve at the inferior vena cava position, and confirmed anatomical suitability for orthotopic transcatheter tricuspid valve replacement (TTVR). The patient subsequently underwent successful Evoque TTVR, achieving complete TR abolition and TricValve unloading. DISCUSSION AND TAKE-HOME MESSAGES: This case highlights the versatility of TTVR as a comprehensive solution for clinically significant TR. Guided by advanced multimodality imaging, Evoque TTVR effectively provided definitive TR correction without any device interaction in a complex anatomical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.